Curis Reports Narrowed Q2 Loss Amid Clinical Progress, Revenue Growth

Curis Inc., a biotechnology company developing targeted cancer therapies, reported its Q2 2025 financial and clinical progress, showing a narrowed GAAP net loss of $8.6 million ($0.68 per share), outperforming analyst expectations and improving from $11.8 million in Q2 2024. Revenues slightly increased to $2.7 million, primarily from royalty payments for Erivedge, a marketed skin cancer drug. The company is advancing clinical trials of its lead asset, emavusertib, targeting blood cancers including lymphoma, leukemia, and chronic lymphocytic leukemia, with ongoing studies critical for regulatory approval and future commercialization. Curis also reduced its research and development and administrative expenses, contributing to improved financial results, though it noted that current cash reserves are sufficient only through Q1 2026 without new funding. Analysts like Sara Nik of H.C. Wainwright have maintained a Buy rating with a $17 price target, citing promising clinical progress and financial performance. Despite recent stock underperformance, Curis's strategic focus on clinical advancements and pipeline expansion positions it for potential growth in addressing unmet medical needs in oncology.